CoQ10 and D-ribose in Patients With Diastolic Heart Failure

• Status: Completed
• Trial end date: 2021-03-12
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the clinical benefits of CoQ10 and D-ribose taken by patients who have diastolic heart failure, or heart failure with preserved ejection fraction (HFpEF).

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Kansas Medical Center
• Collaborator: National Institute on Aging (NIA)
• Treatments: Coenzyme Q10

Criteria

Inclusion Criteria:

• Diagnosed with HFpEF within a 6-month period

• New York Heart Association (NYHA) Classification II-III HF

• Have left ventricular ejection fraction (EF) ≥ 50% documented by an echocardiogram

• Have a telephone or reliable phone contact

• Have their own means of transportation to the study site

Exclusion Criteria:

• Acute coronary syndrome in the past 12 weeks

• Significant valvular heart disease

• Severe cardiac fibrosis (galectin-3 level > 26 ng/ml)

• Constrictive pericardium

• Pulmonary fibrosis

• Congenital heart disease

• Hypertrophic or infiltrative cardiomyopathy

• Heart transplant

• Left ventricular assist device

• Heart failure (HF) associated hospital admission or emergency room visit within past 30 days

• Recent percutaneous coronary intervention

• Significant renal and/or hepatic dysfunction

• Severe cognitive impairment

• Consumption of any CoQ10 (ubiquinol) or D-ribose supplements